WALTHAM, Mass.–Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has been selected as the National Children’s Study (NCS) biological and environmental sample repository partner. The study examines the effects of environmental influences on the health and development of 100,000 children across the United States, following them from before birth until age 21. The contract was awarded to the company’s Fisher BioServices business by the National Institutes of Health in conjunction with a consortium that includes the Centers for Disease Control and Prevention and the Environmental Protection Agency.

“This is a monumental study that stands to transform our knowledge of human development, provide insight into diseases and push medical research forward,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “We’re honored to play such an important role in this work. The project demands the careful handling and storing of countless samples over many years, and Fisher BioServices’ track record as the leader in biorepository services made this an ideal alliance.”

The company will establish a biorepository to handle the organization, storing and disbursement of patient specimens and environmental samples for the duration of the study. Expert personnel will monitor specimen integrity over time and the Fisher BioServices IN-TRAK® inventory management system will interface with the NCS information management system to give researchers on-line access to stored samples.

Fisher BioServices is a professional contract services business with more than 23 years of experience in biological repository services and cold chain logistics, managing high value biological specimens, cell-based therapeutics, vaccines and tissues. The business manages more than 170,000,000 samples globally, serving more than 30 governments and 300 commercial customers.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With 2008 revenues of $10.5 billion, we have approximately 34,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com.

This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company’s Quarterly Report on Form 10-Q for the period ended September 26, 2009, under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investors” section of our Website under the heading “SEC Filings.” Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; general worldwide economic conditions and related uncertainties; dependence on customers’ capital spending policies and government funding policies; the effect of exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; the effect of laws and regulations governing government contracts; the effect of competing with certain of our customers and suppliers; and the effect of rapid changes in the healthcare industry. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.